Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004 Post published:June 16, 2021 Post category:Press Release
Bright Minds Biosciences Announces Application to List on Nasdaq Post published:June 16, 2021 Post category:Press Release
Optimi Health Completes Pre-Clinical Trial Application Meeting Post published:June 15, 2021 Post category:Press Release
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression Post published:June 15, 2021 Post category:Press Release
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound Post published:June 15, 2021 Post category:Press Release
Psychedelic Research Bulletin: May 2021 Post published:June 14, 2021 Post category:Psychedelics Research Review
Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation Post published:June 11, 2021 Post category:Psychedelic Bulletin
Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin Post published:June 11, 2021 Post category:Press Release
atai Life Sciences Announces Launch of Initial Public Offering Post published:June 11, 2021 Post category:Press Release